Stockscreener 앱 받기
11.30
0.35%
-0.04
시간 외 거래:
11.30
Viatris Inc 주식(VTRS)의 최신 뉴스
Why Is Viatris Inc. (VTRS) Among the Best High-Yield Dividend Stocks to Invest In? - Insider Monkey
EU Antitrust Chief Ribera: Consumer Protections Remain Top Priority - PYMNTS.com
Viatris Launch Plans Continue To Drag On, But Confidence High On Quartet - News & Insights
Is Viatris Inc. (VTRS) Among Wednesday’s Losers? - MSN
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc (VTRS) Stock Price Down 4.56% on Jan 15 - GuruFocus.com
Is Viatris (VTRS) a Great Value Stock Right Now? - Yahoo Finance
Viatris firm in Cork paid $4bn of dividends as sales fell ahead of announced plant closure - Business Post
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical Trials Progress and Therapeutic Advancements | Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, Roche - Barchart
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical - openPR
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.
Is Viatris (VTRS) the Best Medical Stock to Buy Under $20? - Insider Monkey
Viatris Enters Oversold Territory - Nasdaq
Viatris Stock: Is VTRS Outperforming the Healthcare Sector? - MSN
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc - The Globe and Mail
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA - openPR
Another Disappointing Drug Import Alert from India - The People's Pharmacy
When (VTRS) Moves Investors should Listen - Stock Traders Daily
US FDA Blocks 11 Viatris Products, Except Four With Shortage Concerns - News & Insights
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Con - GuruFocus.com
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
Maternal Mental Health Market Is Booming Worldwide 2025-2032 | - openPR
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris (VTRS) Shares Cross 4% Yield Mark - Nasdaq
Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes (NASDAQ:VTRS) - Seeking Alpha
FDA Blocks Viatris US Products With India Facility Import Alert - News & Insights
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Fierce Pharma Asia—Roche, Innovent's ADC deal; Lessons from AZ's China probes; Viatris' warning letter - FiercePharma
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus.com
Viatris Inc. stock falls Monday, still outperforms market - MarketWatch
Maternal Mental Health Market Set to Witness Significant Growth by 2024-2031: Canopie, Pfizer Inc, Viatris - EIN News
Viatris Inc. stock falls Friday, still outperforms market - MarketWatch
Viatris Stock: Is VTRS Outperforming The Healthcare Sector? - Barchart
Viatris receives FDA warning letter for 11 drugs made at India plant - MSN
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris faces FDA import restrictions at Indian facility - The Pharma Letter
Viatris confirms receipt of warning letter, import alert for India facility - TipRanks
Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference - Kilgore News Herald
US FDA restricts imports of some Viatris drugs made at India facility - Reuters
FDA restricts import of certain Viatris products due to plant violations - Investing.com UK
Viatris says India plant hit with FDA warning letter, import ban on 11 products - FiercePharma
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
What Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn? - Insider Monkey
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology - The Malaysian Reserve
0.05%
0.94%
자본화:
|
볼륨(24시간):